---
title: "Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China | SMMT Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288174204.md"
description: "Akeso's HARMONi-6 study in China shows Ivonescimab combined with chemotherapy achieved a statistically significant overall survival benefit compared to Tislelizumab plus chemotherapy for first-line treatment of squamous non-small cell lung cancer (NSCLC)."
datetime: "2026-05-31T05:10:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288174204.md)
  - [en](https://longbridge.com/en/news/288174204.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288174204.md)
---

# Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China | SMMT Stock News

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China | SMMT Stock News

### Related Stocks

- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)
- [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)
- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)

## Related News & Research

- [BeOne Medicines Sets Out Board and Committee Structure to Bolster Governance](https://longbridge.com/en/news/289523795.md)
- [BeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive Plans](https://longbridge.com/en/news/289522339.md)
- [Summit Therapeutics Co-Chief Executive Officer Purchased Shares Worth Over $49M](https://longbridge.com/en/news/289622557.md)
- [UBS Reaffirms Their Buy Rating on Akeso, Inc. (9926)](https://longbridge.com/en/news/289649001.md)
- [China’s NMPA approves Akeso’s gumokimab for plaque psoriasis](https://longbridge.com/en/news/289582499.md)